Exasol (EXL) Q4 2024 TU earnings summary

Executive summary

• Achieved sustainable profitability in 2024, with positive EBITDA, net income, and cash flow for the first time since IPO, after years of losses.

• Strategic focus on on-premise and hybrid verticals, especially finance and healthcare, drove growth and 19% ARR increase in these segments.

• Transformation underway to shift portfolio toward regulated, high-retention verticals and away from non-focus areas.

• Signed 10 new customers worth €700k and secured a major five-year upsell deal exceeding €10 million.

• Growth in focus verticals offset by higher churn in non-focus verticals, particularly in H1 2024.

Financial highlights

• EBITDA reached EUR 2.0 million in 2024, up from EUR -5.7 million in 2023, exceeding initial targets.

• Net income improved by EUR 8.5 million to EUR 0.3 million year-over-year.

• Revenue grew 12.8% year-over-year to EUR 39.6 million.

• Annual Recurring Revenue (ARR) ended at EUR 42.3 million, up 3.7% year-over-year.

• Cash balance increased to EUR 15.0 million by year-end, exceeding expectations.

Outlook and guidance

• 2025 guidance targets mid-single digit growth in ARR and revenue.

• Targeting at least 50% EBITDA growth to EUR 3–4 million in 2025.

• Anticipate continued portfolio shift, with focus verticals reaching 70% of business by end of 2025.

• Aim to return to double-digit growth after 2025 as transition completes.

• Liquid funds and positive net income expected to increase again in 2025.